Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus (2025)
Cogliano, Vincent J; Corsini, Emanuela 
; Fournier, Agnès ; Nelson, Heather H; Sergi, Consolato M; Antunes, Alexandra M. M; Cahoon, Elizabeth K; Chen, Guosheng; Salles, Talita Duarte ; Engels, Eric; Fu, Jingqi; Germolec, Dori; Ghiasvand, Reza; Hicks, Blánaid; Claude, Bertrand J. Jean; Jena, Gopabandhu; Lerche, Catharina M ; Lupattelli, Angela; Ong, Thomas Prates
Source: The Lancet Oncology. Unidade: FCF
Subjects: CARCINOGÊNESE, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COGLIANO, Vincent J et al. Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus. The Lancet Oncology, v. 26, n. 1, p. 15-16, 2025Tradução . . Disponível em: https://dx.doi.org/10.1016/S1470-2045(24)00685-5. Acesso em: 01 maio 2026.APA
Cogliano, V. J., Corsini, E., Fournier, A., Nelson, H. H., Sergi, C. M., Antunes, A. M. M., et al. (2025). Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus. The Lancet Oncology, 26( 1), 15-16. doi:10.1016/S1470-2045(24)00685-5NLM
Cogliano VJ, Corsini E, Fournier A, Nelson HH, Sergi CM, Antunes AMM, Cahoon EK, Chen G, Salles TD, Engels E, Fu J, Germolec D, Ghiasvand R, Hicks B, Claude BJJ, Jena G, Lerche CM, Lupattelli A, Ong TP. Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus [Internet]. The Lancet Oncology. 2025 ; 26( 1): 15-16.[citado 2026 maio 01 ] Available from: https://dx.doi.org/10.1016/S1470-2045(24)00685-5Vancouver
Cogliano VJ, Corsini E, Fournier A, Nelson HH, Sergi CM, Antunes AMM, Cahoon EK, Chen G, Salles TD, Engels E, Fu J, Germolec D, Ghiasvand R, Hicks B, Claude BJJ, Jena G, Lerche CM, Lupattelli A, Ong TP. Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus [Internet]. The Lancet Oncology. 2025 ; 26( 1): 15-16.[citado 2026 maio 01 ] Available from: https://dx.doi.org/10.1016/S1470-2045(24)00685-5
